Endokrynologia Polska最新文献

{"title":"Ectopic ACTH syndrome in the course of ACTH-secreting pancreatic neuroendocrine tumour in a patient with a pituitary lesion - diagnostic challenges and individual approach.","authors":"Joanna Sobolewska, Łukasz Działach, Wioleta Respondek, Agnieszka Wojciechowska-Luźniak, Przemysław Witek","doi":"10.5603/ep.97357","DOIUrl":"10.5603/ep.97357","url":null,"abstract":"<p><p>Not required for Clinical Vignette.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":"75 1","pages":"113-114"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low triiodothyronine syndrome and depression: a cross-sectional study in the elderly based on comprehensive geriatric assessment.","authors":"Qian Xue, Yanru Ma, Xia Li, Lihua Deng, Jingtong Wang","doi":"10.5603/ep.97956","DOIUrl":"10.5603/ep.97956","url":null,"abstract":"<p><strong>Introduction: </strong>Thyroid diseases such as low triiodothyronine syndrome (LT3S) are more common in the elderly population. Comprehensive geriatric assessment (CGA) has been proposed as a supplementary tool for evaluating medical, functional, psychological, and frailty status and various geriatric syndromes. This study aimed to evaluate the impact of thyroid diseases on overall health status using a novel CGA strategy.</p><p><strong>Material and methods: </strong>477 patients were enrolled between January 2019 and December 2022. A structured CGA was conducted by a multidisciplinary team to identify older high-risk patients. Multivariate regression was performed to assess independent factors associated with thyroid status and CGA.</p><p><strong>Results: </strong>The prevalence of abnormal thyroid hormone levels in the elderly was 34.2%. LT3S and anti-thyroglobulin antibody (anti-TgAb)-positivity or anti-thyroid peroxidase antibody (anti-TPOAb)-positivity were the main manifestations of thyroid diseases in elderly patients. The patients with LT3S had a higher prevalence of diabetes (p = 0.023), were older (p = 0.000), more often female (p = 0.014), with higher C-reactive protein (p = 0.001), and with lower body mass index (BMI) (p = 0.002), albumin (Alb) (p = 0.000), and haemoglobin (Hb) (p = 0.000) than patients with normal thyroid function. The CGA results showed higher rates of malnutrition and depression in patients with LT3S. Further multivariate logistic regression analysis showed that Hb [odds ratio (OR): 0.975; 95% confidence interval (CI): 0.959-0.990; p = 0.002] and LT3S (OR: 2.213; 95% CI: 1.048-4.672; p = 0.037) were independently associated with depression. Female (OR: 0.393; 95% CI: 0.160-0.968; p = 0.042), Alb (OR: 0.892; 95% CI: 0.811-0.981; p = 0.018), Hb (OR, 0.964; 95% CI: 0.939-0.989; p = 0.006), and LT3S (OR: 3.749; 95% CI: 1.474-9.536; p = 0.006) were independently associated with malnutrition.</p><p><strong>Conclusions: </strong>LT3S was closely related to depression and malnutrition. Physicians should be more concerned about elderly patients with LT3S for their physical and mental status. Regular thyroid function checks might help to detect depression earlier.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":"75 1","pages":"42-50"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of disease recurrence in patients after complete pancreatic NET (PanNET) G2 resection.","authors":"Helena Olearska, Anna Sowa-Staszczak, Karolina Morawiec-Sławek, Anna Kurzyńska, Magdalena Kolasa, Edyta Tkacz, Małgorzata Szumińska, Alicja Hubalewska-Dydejczyk, Marta Opalinska","doi":"10.5603/ep.98635","DOIUrl":"10.5603/ep.98635","url":null,"abstract":"<p><strong>Introduction: </strong>The number of detected pancreatic neuroendocrine tumours (PanNETs) has been increasing over the last decades. Surgical resection remains the only potentially curative treatment, but the management is still controversial. This study aimed to compare patients after radical PanNET G2 resection to determine the most important predictive factors for relapse.</p><p><strong>Material and methods: </strong>All patients with histologically confirmed PanNET G2 who underwent successful surgery between 2006 and 2020 with the intention of radical treatment were enrolled.</p><p><strong>Results: </strong>In total, 44 patients were eligible for the analysis. The average follow-up was 8.39 ± 4.5 years. Disease recurrence was observed in 16 (36.36%) patients. The dominant location of the primary tumour was the tail of the pancreas (43.18%), especially in the subgroup with disease recurrence (56.25%). The smallest tumour diameter associated with the PanNET G2 recurrence was 22 mm. The relationship between the largest dimension of the tumour with a division of < 4 cm vs. > 4 cm and the relapse was close to statistical significance. Recurrence was associated with a larger tumour size (p = 0.018). There was a statistically significant relationship and a weak correlation between Ki-67 (p = 0.036, V Cramer = 0.371) and disease relapse.</p><p><strong>Conclusion: </strong>For the group of PanNET G2 patients after radical surgery, the overall risk of recurrence was 36.36%, with the highest rate in the first 5 years after surgery, but in individual cases it occurred significantly later, even 10 years after surgery. The most important predictive factors of the PanNET G2 recurrence was Ki-67 over 5.75% and size of tumour > 4 cm.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":"75 1","pages":"102-108"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progress in research on ablation of thyroid nodules.","authors":"Ze Yang, Xue-Hua Pan, Heng-Tong Han, Yong-Xun Zhao, Li-Bin Ma","doi":"10.5603/ep.98908","DOIUrl":"10.5603/ep.98908","url":null,"abstract":"<p><p>The incidence of thyroid nodules is rising annually. Surgical treatment is effective, but often results in significant trauma, recurrent laryngeal nerve injury, hypoparathyroidism, and other complications. Recent years have seen significant breakthroughs in thyroid nodule ablation for treating thyroid diseases, although its application remains controversial. The objective was to review the development history and current research status of thyroid nodule ablation to provide a reference for future studies. The literature on thyroid nodule ablation was reviewed, analysing its advantages and disadvantages. The therapeutic effect of thyroid nodule ablation in treating benign thyroid lesions is noteworthy, but issues such as lax treatment indications and excessive medical treatment persist. Initial success has been achieved in treating thyroid malignant lesions, particularly papillary thyroid microcarcinoma (PTMC). However, the curative effect requires further follow-up verification.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":" ","pages":"262-266"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141422237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Primary hyperparathyroidism in pregnancy].","authors":"Jacek Gawrychowski","doi":"10.5603/ep.99402","DOIUrl":"10.5603/ep.99402","url":null,"abstract":"","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":" ","pages":"235-236"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141461391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of parathormone-dependent hypercalcaemia in the third-trimester of pregnancy.","authors":"Mateusz Zamłyński, Anita Olejek, Grzegorz Buła, Adrianna Marzec, Agata Gawrychowska, Jacek Gawrychowski","doi":"10.5603/ep.99387","DOIUrl":"10.5603/ep.99387","url":null,"abstract":"<p><p>Not required for Clinical Vignette.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":" ","pages":"336-337"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141422240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is [68Ga]Ga-DOTA-TATE PET/CT useful in the diagnosis of patients suspected of ectopic Cushing's syndrome?","authors":"Alain Iskandar, Anna Zemczak, Kacper Pełka, Jolanta Kunikowska","doi":"10.5603/ep.100560","DOIUrl":"https://doi.org/10.5603/ep.100560","url":null,"abstract":"<p><strong>Introduction: </strong>Ectopic Cushing's syndrome (ECS) presents significant diagnostic and management challenges due to its varied clinical presentation and diagnostic uncertainties associated with conventional imaging methods. The aim of this study was to evaluate the effectiveness of [⁶⁸Ga]Ga-DOTA-TATE positron emission tomography/computed tomography (PET/CT) in diagnosing patients suspected of ECS with negative results from conventional imaging techniques.</p><p><strong>Material and methods: </strong>In this retrospective single-institution study, data from January 2010 to August 2023 were analysed. Patients who underwent [⁶⁸Ga]Ga-DOTA-TATE PET/CT (Siemens Biograph 64) scans due to clinical and biochemical indicators of Cushing's syndrome were included, with prior conventional imaging yielding no abnormalities. The PET/CT scans were analysed qualitatively and quantitatively for any pathological foci. The study was conducted in accordance with ethical standards and approved by the Medical University of Warsaw's ethics committee.</p><p><strong>Results: </strong>Of the 56 [68Ga]Ga-DOTA-TATE PET/CT scans performed on 44 patients, pathological accumulations were identified in 6 scans (11%) and 4 (9%) patients. Pathological findings were exclusively located within the thoracic cavity; lung lesions were identified in 3 patients, and 3 independent lesions within the anterior mediastinum and breast were observed in a single patient across 3 distinct scans. Histopathological analysis confirmed neuroendocrine tumours in all patients.</p><p><strong>Conclusions: </strong>[⁶⁸Ga]Ga-DOTA-TATE PET/CT demonstrated limited potential for diagnostic value in patients suspected of ECS with negative outcomes according to conventional imaging. The percentage of patients who achieved positive results (10%) was not high, although other negative tests represented a significant percentage of the patients. This study highlights the need for further research and the development of novel radiotracers to improve ECS diagnosis.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":"75 6","pages":"649-654"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143652727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Possible changes in glucose metabolism induced by radioligand therapy in patients with neuroendocrine neoplasms.","authors":"Marek Saracyn, Adam Daniel Durma, Barbara Bober, Arkadiusz Lubas, Anna Drozd, Gabriela Różańska-Grzelak, Katarzyna Janiak, Dorota Brodowska-Kania, Grzegorz Kamiński","doi":"10.5603/ep.101234","DOIUrl":"https://doi.org/10.5603/ep.101234","url":null,"abstract":"<p><strong>Introductiom: </strong>Neuroendocrine neoplasms (NENs) belong to a heterogeneous group of tumours originating from neuroendocrine cells. Primary tumours most commonly occur in the gastrointestinal tract, although they can arise in any part of the human body. Radioligand therapy (RLT) is recommended for progressive or inoperable cases in subsequent lines of the therapy. Our study aimed to investigate glucose metabolism alterations during and after radioligand therapy in patients with neuroendocrine neoplasms undergoing radioligand therapy.</p><p><strong>Material and methods: </strong>The study was performed on 41 patients with inoperable neuroendocrine tumours, who underwent one cycle (4 courses) of radioligand therapy with [¹⁷⁷Lu]Lu-DOTA-TATE alone or tandem therapy with [¹⁷⁷Lu]Lu-DOTA-TATE and [⁹⁰Y]Y-DOTA-TATE with a standardised nephroprotection protocol. Laboratory parameters were analysed during the first and fourth courses and one year after the last course of treatment.</p><p><strong>Results: </strong>The study showed a statistically insignificant increase in fasting glucose concentration during and after radioligand therapy, accompanied by a parallel increase in insulin concentration. In patients treated with tandem therapy, the increase in fasting glucose was higher, but the results were still statistically insignificant. No glycaemic severe adverse events [Common Terminology Criteria for Adverse Events (CTCAE) G3-G5] were observed.</p><p><strong>Conclusions: </strong>Radioligand therapy potentially increases fasting glucose concentrations, probably due to changes in peripheral glucose metabolism. However, it remains a safe treatment method for patients with neuroendocrine neoplasms and does not cause severe glycaemic adverse events related to glucose metabolism.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":"75 6","pages":"665-671"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143652782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The position of monoclonal antibodies and small molecules in the treatment of thyroid orbitopathy.","authors":"Mariusz Nowak, Wojciech Nowak, Bogdan Marek, Beata Kos-Kudła, Lucyna Siemińska, Magdalena Londzin-Olesik, Dariusz Kajdaniuk","doi":"10.5603/ep.98913","DOIUrl":"https://doi.org/10.5603/ep.98913","url":null,"abstract":"<p><p>Since the European Thyroid Association guidelines for the management of thyroid orbitopathy (TO) were published in 2016, a number of randomised clinical trials (RCTs) investigating the use of biologic drugs for the treatment of moderate to severe and active TO have been published. Therefore, new recommendations for its treatment were developed and published in 2021. Treatment of active TO includes 2 types of immunosuppressive agents: non-specific and specific. Specific immunosuppressive agents used to treat TO include adalimumab (ADA), infliximab (IFX), etanercept (ETA), rituximab (RTX), tocilizumab (TCZ), teprotumumab (TEP), and batoclimab (BAT). In the manuscript, we present a review of the literature on RCTs, retrospective studies, and case reports on their use in the treatment of TO. The authors emphasise the beneficial effects of TEP, indicating, however, the lack of data on its long-term efficacy and safety and the lack of head-to-head comparison with i.v. glucocorticosteroids and its huge limitation is also the high price of the drug. TCZ is a therapeutic option for glucocorticosteroid-resistant TO and should be considered for second-line treatment (due to the cost of treatment, among other reasons) or first-line treatment in patients with contraindications to i.v. glucocorticosteroids. Given its side-effect profile, especially some risk of optic nerve neuropathy (DON), RTX is considered by the authors as a second- or even third-line treatment option. The current 2021 European Group on Graves' Orbitopathy (EUGOGO) recommendations include RTX, TCZ, and TEP among the second-line drugs for the treatment of moderate to severe and active TO. BAT is under clinical trials. Given the numerous advantages of biologic drugs over glucocorticosteroids, further RCTs are indicated to confirm their possible place also as first-line treatment in TO.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":"75 6","pages":"604-616"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143652786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes and long-term follow-up after radioligand therapy in aggressive non-functioning pituitary neuroendocrine tumour.","authors":"Dorota Brodowska-Kania, Marek Saracyn, Natalia Osial, Adam Daniel Durma, Maciej Kołodziej, Grzegorz Kamiński","doi":"10.5603/ep.101015","DOIUrl":"10.5603/ep.101015","url":null,"abstract":"<p><p>Not required for Clinical Vignette.</p>","PeriodicalId":93990,"journal":{"name":"Endokrynologia Polska","volume":"75 6","pages":"693-694"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143652766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}